Although the efficacy of PI3K inhibitors has been reported in a variety of tumours, and several inhibitors have been approved for marketing, the serious and even lethal toxicity they cause remains a problem that cannot be ignored (De Santis et al. 2019). This evidence concerns the gene PIK3CA and neoplasm.